

Supplementary information

***In Vitro* Models of Oxidative Stress, Mitochondrial Dysfunction and Inflammation for Evaluation of Neuroprotective Biomaterials**

Fucen Luo^a, Thelma Akanchise^a, Borislav Angelov^b, and Angelina Angelova^{*a}


^a. Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France,

^b. Extreme Light Infrastructure ERIC, CZ-25241 Dolni Brezany, Czech Republic.

*Corresponding author: angelina.angelova@universite-paris-saclay.fr

Table S1 Composition of lipid nanoparticles and the respective mass proportions of the components

Sample Code	Formulations of Lipid Nanoparticles
MPLu	Monoolein (90%)/Pluronic F127(10%)
MPL	Monoolein (30%)/Plasmalogen (60%)/Pluronic F127(10%)
MPL-MT	Monoolein (28.4%)/Plasmalogen (56.6%)/Pluronic F127 (10%)/ Melatonin (5%)
MPL-Quer	Monoolein (29.4%)/Plasmalogen (58.6%)/Pluronic F127 (10%)/ Quercetin (2%)



Sample	MPLu	MPL	MPL-MT
size (nm)	329.4 ± 3.1	154.5 ± 3.6	146.3 ± 2.15
PDI	0.276 ± 0.012	0.252 ± 0.020	0.219 ± 0.010

Figure S1. Size distributions and Polydispersity index (PDI) of liquid crystalline nanoparticles (MPLu, MPL, MPL-MT) determined by dynamic light scattering. Data are presented as average ± SD (n=3).